Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.29M | 3.22M | 40.90M | 128.23M | 5.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.29M | 3.22M | 40.90M | 128.23M | 5.68M |
| Cost of Revenue | 29.74M | 39.17M | 34.30M | 40.45M | 35.21M |
| Gross Profit | -22.45M | -35.95M | 6.60M | 87.78M | -29.53M |
| SG&A Expenses | 21.62M | 28.57M | 21.28M | 19.08M | 19.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.36M | 67.74M | 55.58M | 59.53M | 54.94M |
| Operating Income | -44.07M | -64.51M | -14.68M | 68.70M | -49.26M |
| Income Before Tax | -47.01M | -72.52M | -16.79M | 70.05M | -47.98M |
| Income Tax Expenses | 575.00K | 1.69M | 831.00K | 526.00K | 526.00K |
| Earnings from Continuing Operations | -47.58M | -74.22M | -17.62M | 69.52M | -48.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.58M | -74.22M | -17.62M | 69.52M | -48.50M |
| EBIT | -44.07M | -64.51M | -14.68M | 68.70M | -49.26M |
| EBITDA | -41.61M | -61.68M | -11.86M | 71.44M | -46.43M |
| EPS Basic | -1.11 | -1.74 | -0.41 | 1.63 | -1.20 |
| Normalized Basic EPS | -0.11 | -0.16 | -0.04 | 0.17 | -0.12 |
| EPS Diluted | -1.11 | -1.85 | -0.41 | 1.44 | -1.20 |
| Normalized Diluted EPS | -0.11 | -0.16 | -0.04 | 0.17 | -0.12 |
| Average Basic Shares Outstanding | 257.03M | 255.92M | 255.77M | 255.59M | 241.87M |
| Average Diluted Shares Outstanding | 42.84M | 42.65M | 42.63M | 43.31M | 40.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |